ORGO Fundamental Analysis - ORGANOGENESIS HOLDINGS INC

Fundamental Rating

ORGO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. ORGO has only an average score on both its financial health and profitability. While showing a medium growth rate, ORGO is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ORGO had negative earnings in the past year.

ORGO had a negative operating cash flow in the past year.

Of the past 5 years ORGO 4 years were profitable.

ORGO had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -3.38%, ORGO belongs to the top of the industry, outperforming 87.80% of the companies in the same industry.

ORGO has a better Return On Equity (-4.32%) than 90.02% of its industry peers.

		Industry Rank	Sector Rank
ROA	-3.38%
ROE	-4.32%
ROIC	N/A

ROA(3y)1.45%

ROA(5y)6.32%

ROE(3y)2.46%

ROE(5y)11.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ORGO's Operating Margin has declined in the last couple of years.

ORGO has a Gross Margin of 74.58%. This is amongst the best in the industry. ORGO outperforms 82.62% of its industry peers.

ORGO's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for ORGO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	74.58%

OM growth 3Y-34.07%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.17%

GM growth 5Y1.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ORGO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ORGO has been reduced compared to 1 year ago.

Compared to 5 years ago, ORGO has more shares outstanding

ORGO has a better debt/assets ratio than last year.

2.2 Solvency

ORGO has an Altman-Z score of 4.62. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.

With a decent Altman-Z score value of 4.62, ORGO is doing good in the industry, outperforming 75.79% of the companies in the same industry.

ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.00, ORGO is in line with its industry, outperforming 50.28% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	4.62

ROIC/WACCN/A

WACC9.99%

2.3 Liquidity

ORGO has a Current Ratio of 3.95. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.

ORGO's Current ratio of 3.95 is in line compared to the rest of the industry. ORGO outperforms 45.10% of its industry peers.

ORGO has a Quick Ratio of 3.45. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 3.45, ORGO is in line with its industry, outperforming 42.14% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.95
Quick Ratio	3.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -225.00%.

The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad

ORGO shows a decrease in Revenue. In the last year, the revenue decreased by -4.20%.

The Revenue has been growing by 13.05% on average over the past years. This is quite good.

EPS 1Y (TTM)-225%

EPS 3Y-37.9%

EPS 5YN/A

EPS Q2Q%-350%

Revenue 1Y (TTM)-4.2%

Revenue growth 3Y0.98%

Revenue growth 5Y13.05%

Sales Q2Q%-22.44%

3.2 Future

ORGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.28% yearly.

Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 12.92% on average per year.

EPS Next Y-112%

EPS Next 2Y-11.68%

EPS Next 3Y20.28%

EPS Next 5YN/A

Revenue Next Year4.04%

Revenue Next 2Y14.25%

Revenue Next 3Y12.92%

Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ORGO. In the last year negative earnings were reported.

With a Price/Forward Earnings ratio of 34.54, ORGO can be considered very expensive at the moment.

90.20% of the companies in the same industry are more expensive than ORGO, based on the Price/Forward Earnings ratio.

The average S&P500 Price/Forward Earnings ratio is at 22.86. ORGO is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	34.54

4.2 Price Multiples

89.28% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	160.85

4.3 Compensation for Growth

ORGO's earnings are expected to grow with 20.28% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-11.68%

EPS Next 3Y20.28%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ORGO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (9/19/2025, 8:00:02 PM)

After market: 4.58 0 (0%)

4.58

-0.17 (-3.58%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-07 2025-08-07/amc

Earnings (Next)11-10 2025-11-10/amc

Inst Owners54.13%

Inst Owner Change7.15%

Ins Owners31.29%

Ins Owner Change0.23%

Market Cap581.02M

Analysts85

Price Target8.16 (78.17%)

Short Float %15.11%

Short Ratio13.04

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-73%

Min EPS beat(2)-73%

Max EPS beat(2)-73%

EPS beat(4)2

Avg EPS beat(4)278.21%

Min EPS beat(4)-73%

Max EPS beat(4)688.24%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-5.3%

Min Revenue beat(2)-6.36%

Max Revenue beat(2)-4.23%

Revenue beat(4)2

Avg Revenue beat(4)1.61%

Min Revenue beat(4)-6.36%

Max Revenue beat(4)13.3%

Revenue beat(8)4

Avg Revenue beat(8)0.38%

Revenue beat(12)5

Avg Revenue beat(12)0.07%

Revenue beat(16)6

Avg Revenue beat(16)-0.09%

PT rev (1m)14.29%

PT rev (3m)28%

EPS NQ rev (1m)22.22%

EPS NQ rev (3m)-35.29%

EPS NY rev (1m)0%

EPS NY rev (3m)-130.77%

Revenue NQ rev (1m)1.9%

Revenue NQ rev (3m)-3.64%

Revenue NY rev (1m)-0.06%

Revenue NY rev (3m)-0.11%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	34.54
P/S	1.35
P/FCF	N/A
P/OCF	N/A
P/B	1.61
P/tB	1.81
EV/EBITDA	160.85

EPS(TTM)-0.05

EYN/A

EPS(NY)0.13

Fwd EY2.9%

FCF(TTM)-0.37

FCFYN/A

OCF(TTM)-0.26

OCFYN/A

SpS3.39

BVpS2.85

TBVpS2.54

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-3.38%
ROE	-4.32%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	74.58%
FCFM	N/A

ROA(3y)1.45%

ROA(5y)6.32%

ROE(3y)2.46%

ROE(5y)11.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)4.79%

ROCE(5y)9.27%

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-34.07%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.17%

GM growth 5Y1.4%

F-Score3

Asset Turnover0.93

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	0.03
Cap/Depr	74.48%
Cap/Sales	3.07%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.95
Quick Ratio	3.45
Altman-Z	4.62

F-Score3

WACC9.99%

ROIC/WACCN/A

Cap/Depr(3y)177.81%

Cap/Depr(5y)208.05%

Cap/Sales(3y)5.07%

Cap/Sales(5y)5.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-225%

EPS 3Y-37.9%

EPS 5YN/A

EPS Q2Q%-350%

EPS Next Y-112%

EPS Next 2Y-11.68%

EPS Next 3Y20.28%

EPS Next 5YN/A

Revenue 1Y (TTM)-4.2%

Revenue growth 3Y0.98%

Revenue growth 5Y13.05%

Sales Q2Q%-22.44%

Revenue Next Year4.04%

Revenue Next 2Y14.25%

Revenue Next 3Y12.92%

Revenue Next 5YN/A

EBIT growth 1Y-221.35%

EBIT growth 3Y-33.42%

EBIT growth 5YN/A

EBIT Next Year510.28%

EBIT Next 3Y111.89%

EBIT Next 5YN/A

FCF growth 1Y-140.26%

FCF growth 3Y-48.6%

FCF growth 5YN/A

OCF growth 1Y-297.24%

OCF growth 3Y-38.8%

OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens